Aarkstore Enterprise-Threshold Pharmaceuticals, Inc. (THLD) - Financial and Strategic Analysis Revie

PRLog (Press Release) - Aug 03, 2010 -
Threshold Pharmaceuticals, Inc. (THLD) - Financial and Strategic Analysis Review

Threshold Pharmaceuticals, Inc.(Threshold Pharmaceuticals) is a biotechnology company, engaged in the discovery and development of therapeutics for the treatment of cancer. The company focuses on the hypoxic microenvironment of tumor cells and less toxic to healthy tissues than conventional treatments. Its product pipeline includes TH-302, a hypoxia-activated prodrug (HAP) for the potential treatment of solid tumors; Glufosfamide in combination with gemcitabine for the treatment of advanced pancreatic cancer and 2-Deoxyglucose, or 2DG, for the treatment of solid tumors. The company's product candidates are focused on treating patients with significant unmet medical needs.

Threshold Pharmaceuticals, Inc. Key Recent Developments

May 12, 2010: Threshold Names David Parkinson To Board Of Directors
May 07, 2010: Threshold Pharmaceuticals Reports Net Loss Of $6 Million For Q1 2010
Mar 04, 2010: Threshold Pharmaceuticals Reports Net Loss Of $4.7 Million In Q4 2009
Jan 26, 2010: Threshold Reports Phase 1/2 Clinical Trial Of TH-302
Nov 06, 2009: Threshold Presents Interim Data From Phase 1/2 Clinical Trial Of TH-302

This comprehensive SWOT profile of Threshold Pharmaceuticals, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of the ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, the highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Threshold Pharmaceuticals, Inc., including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.